Therapeutic N-glycan modulation is highlighted as a promising tumor microenvironment–targeted strategy for PDAC treatment by disrupting tumor–stroma communication and remodeling the tumor microenvironment by disrupting tumor–stroma communication and remodeling the tumor microenvironment.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, characterized by extensive desmoplasia, aggressive metastasis, and profound therapeutic resistance driven by its tumor microenvironment (TME). Increasing evidence suggests that cancer–stromal interactions, particularly those involving cancer-associated fibroblasts (CAFs), play critical roles in promoting tumor progression and immune evasion through Activin A signaling. In parallel, aberrant N-glycosylation has emerged as an important regulator of PDAC malignancy and tumor–stroma communication. In our previous study, we identified ACK900, a selective Golgi α-mannosidase II inhibitor with improved specificity and potent anti-metastatic activity. ACK900 suppresses PDAC progression by targeting glycan-dependent mechanisms within the tumor microenvironment. Mechanistically, ACK900 inhibits complex-type N-glycan formation on ATP1B1, a key mediator of cancer–fibroblast interactions that activate Activin A signaling. Furthermore, ACK900 destabilizes the Activin A receptor ALK4 in CAFs while exhibiting selective effects over normal fibroblasts, suggesting its potential to selectively reprogram the stromal compartment. By disrupting tumor–stroma communication and remodeling the tumor microenvironment, ACK900 effectively reduces cancer cell migration, invasion, and metastatic colonization. These findings highlight therapeutic N-glycan modulation as a promising tumor microenvironment–targeted strategy for PDAC treatment.
Hui-Lan Chang, Chin-Chun Chang, Gita riswana nawung rida, Chun-Mei Hu, Wei-Chieh Cheng. Targeting the tumor microenvironment: A novel therapeutic strategy for pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B124.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by poor therapeutic response and aggressive disease progression driven heavily by the c-MYC oncoprotein. Ubiquitin-specific protease 36 (USP36) is a nucleolar deubiquitinating enzyme that enhances the stability of criti...
Assmaa ElSheikh, Ping-Chuan Zhang, Xiao-Yan Wang et al.· Cancer Research· 0 citations
Leveraging the MITF-dependent gene signature activated in macrophages, this work sought to address how MITF-associated enhancers are mechanistically influencing PDAC TAM functions as the tumor becomes more advanced and develops chemoresistance.
Debbie K. Ledezma, K. Gulay, Hervé Tiriac et al.· Cancer Research· 0 citations
It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.
Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a desmoplastic, immunosuppressive stroma dominated by cancer-associated fibroblasts (CAFs). Paracrine signals from cancer cells and CAFs shape the tumor microenvironment (TME), facilitating interactions that drive tumor growth and immune evasion, yet the mol...
Silvia Pascual-Sabater, Sushmita Varhadi, Marta Celma-Arrufat et al.· Cell Death Discovery· 0 citations
An immunosuppressive tumor microenvironment (TME) is a hallmark of pancreatic ductal adenocarcinoma (PDAC), rendering most tumors resistant to immunotherapy approaches. Importantly, “tumor-to-stroma” crosstalk downstream of oncogenic KRAS has emerged as a major driver of immune evasion in PDAC, however the role of re...
Yuwenbin Li, M. Truitt, Dan Cao et al.· Cancer Research· 0 citations
Key lncRNAs involved in TAM polarization in PDAC are summarized, highlighting their roles in inducing the M2 phenotype and promoting PDAC progression through epigenetic modifications, ceRNA networks, and signal transduction pathways.
Hong-Shi Sun, Jia Wang, Zhong-Bo Xie et al.· Journal of physiology and bi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.